Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Oxurion NV is a biopharmaceutical company. The company is focused on developing treatments to preserve vision for patients with diseases affecting the back of the eye. It has developed a diverse portfolio of disease-modifying drug candidates, including treatments for diabetic eye disease, a leading cause of blindness in people of working age worldwide. It owns the global rights to Jetrea (ocriplasmin), the pharmacological vitreolysis drug approved for the treatment of symptomatic vitreomacular adhesion (in the U.S.) and vitreomacular traction (outside the U.S.).
Leuven, B-3001, Belgium